Jazz Pharmaceuticals plc has announced late-breaking Phase 4 data regarding Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of narcolepsy. The data were presented at SLEEP 2025 as part of four abstracts selected for their scientific quality and innovation by the Associated Professional Sleep Societies (APSS). The Phase 4 XYLO study demonstrated reductions in blood pressure when patients with narcolepsy switched from twice-nightly high-sodium oxybate to low-sodium Xywav. Additionally, the DUET trial evaluated the safety and changes in daytime sleepiness in adults with narcolepsy taking dosages of 9-12 grams of Xywav per night. The results contribute to the ongoing evaluation of Xywav's therapeutic benefits and safety profile.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.